Erythropoiesis stimulating agent administration improves survival after severe traumatic brain injury: A matched case control study

Annals of Surgery

Volumn 251, Issue 1, 2010, Pages 1-4

  Talving, Peep ^a   Lustenberger, Thomas ^a   Kobayashi, Leslie ^a   Inaba, Kenji ^a   Barmparas, Galinos ^a   Schnüriger, Beat ^a   Lam, Lydia ^a   Chan, Linda S ^a   Demetriades, Demetrios ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; ANTIANEMIC AGENT; DRUG DERIVATIVE; ERYTHROPOIETIN; HEMOGLOBIN; NEUROPROTECTIVE AGENT;

ADULT; AGE; AGED; ANEMIA; ARTICLE; BODY REGIONS; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; GENDER; GLASGOW COMA SCALE; HOSPITAL ADMISSION; HUMAN; HYPOTENSION; INJURY SCALE; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL; TRAUMATIC BRAIN INJURY; BLOOD; BRAIN INJURY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; INTENSIVE CARE; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL RATE;

ABBREVIATED INJURY SCALE; ADULT; BRAIN INJURIES; CASE-CONTROL STUDIES; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; FEMALE; GLASGOW COMA SCALE; HEMATINICS; HEMOGLOBINS; HOSPITAL MORTALITY; HUMANS; INJECTIONS, SUBCUTANEOUS; INTENSIVE CARE; LENGTH OF STAY; MALE; NEUROPROTECTIVE AGENTS; SURVIVAL RATE;

EID: 74049110427     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3181b844fa     Document Type: Article

References (23)

1. Grasso G, Sfacteria A, Meli F, et al. Neuroprotection by erythropoietin administration after experimental traumatic brain injury. Brain Res. 2007; 1182:99-105.
2. Verdonck O, Lahrech H, Francony G, et al. Erythropoietin protects from post-traumatic edema in the rat brain. J Cereb Blood Flow Metab. 2007;27: 1369-1376.
3. Grasso G, Buemi M, Alafaci C, et al. Beneficial effects of systemic administration of recombinant human erythropoietin in rabbits subjected to sub-arachnoid hemorrhage. Proc Natl Acad Sci. 2002;99:5627-5631.
4. Xiong Y, Lu D, Qu C, et al. Effects of erythropoietin on reducing brain damage and improving functional outcome after traumatic brain injury in mice. J Neurosurg. 2008;109:510-521.
5. Juul SE, McPherson RJ, Bauer LA, et al. A phase I/II trial of high-dose erythropoietin in extremely low birth weight infants: pharmacokinetics and safety. Pediatrics. 2008;122:383-391.
6. Ehrenreich H, Hasselblatt M, Dembowski C, et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med. 2002;8:495-505.
7. Ehrenreich H, Fischer B, Norra C, et al. Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis. Brain. 2007;130: 2577-2588. (Pubitemid 47511714)
8. Maiese K, Li F, Chong ZZ. New avenues of exploration for erythropoietin. JAMA. 2005;293:90-95.
9. Noguchi CT, Asavaritikrai P, Teng R, et al. Role of erythropoietin in the brain. Crit Rev Oncol Hematol. 2007;64:159-171.
10. Hasselblatt M, Ehrenreich H, Siren AL. The brain erythropoietin system and its potential for therapeutic exploitation in brain disease. J Neurosurg Anes-thesiol. 2006;18:132-138.
11. Robinson Y. Evidence-based management of anaemia in severely injured patients. Acta Anaesthesiol Scand. 2008;52:587-590.
12. Mammis A, McIntosh TK, Maniker AH. Erythropoietin as a neuroprotective agent in traumatic brain injury review. Surg Neurol. 2009;71:527-531.
13. Coleman T, Brines M. Science review: recombinant human erythropoietin in critical illness: a role beyond anemia? Crit Care. 2004;8:337-341.
14. Pacary E, Petit E, Bernaudin M. Erythropoietin, a cytoprotective and regenerative cytokine, and the hypoxic brain. Neurodegener Dis. 2006;3:87-93.
15. Fliser D, Haller H. Erythropoietin and treatment of non-anemic conditions-cardiovascular protection. Semin Hematol. 2007;44:212-217.
16. Brines ML, Ghezzi P, Keenan S, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci. 2000;97:10526-10531.
17. Wang Y, Zhang ZG, Rhodes K, et al. Post-ischemic treatment with erythro-poietin or carbamylated erythropoietin reduces infarction and improves neurological outcome in a rat model of focal cerebral ischemia. Br J Pharmacol. 2007;151:1377-1384.
18. Arcasoy MO. The non-haematopoietic biological effects of erythropoietin. Br J Haematol. 2008;141:14-31.
19. Fauchere JC, Dame C, Vonthein R, et al. An approach to using recombinant erythropoietin for neuroprotection in very preterm infants. Pediatrics. 2008; 122:375-382.
20. Corwin HL, Gettinger A, Fabian TC, et al. Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med. 2007;357:965-976.
21. Napolitano LM, Fabian TC, Kelly KM, et al. Improved survival of critically ill trauma patients treated with recombinant human erythropoietin. J Trauma. 2008;65:285-297; discussion 297-299.
22. Brain Trauma Foundation, American Association of Neurological Surgeons, Congress of Neurological Surgeons, et al. Guidelines for the management of severe traumatic brain injury. I. blood pressure and oxygenation. J Neuro-trauma. 2007;24(suppl 1):S7-S13.
23. Salim A, Hadjizacharia P, DuBose J, et al. Role of anemia in traumatic brain injury. J Am Coll Surg. 2008;207:398-406.